DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Office of Community Services; Grant to the Concordia Avondale Campus

AGENCY: Office of Community Services, ACF, HHS.

ACTION: Award announcement.

SUMMARY: Notice is hereby given that ACF will award grant funds without competition to Concordia Avondale Campus in Chicago, Illinois. This grant is being awarded for a project that conforms to the applicable program objectives, is within legislative authorities, and proposes activities that may be lawfully supported through grant mechanisms. Their grant application is of outstanding and unique merit and presents an opportunity to produce meaningful, sustainable, and useful results in an area of significant interest to ACF.

The Concordia Avondale project will support a two-year effort to provide social and economic services that support low-income, working poor and single-parent families in their communities. These services include child care and after-school programs in the North Center, Lakeview and Ravenswood communities through a sliding scale tuition. The project will be funded at $700,000 for the first year and $800,000 for the second year.

FOR FURTHER INFORMATION CONTACT: Carol Watkins, Office of Community Services on (202) 401–9356.

Dated: November 24, 2003.

Clarence Carter,

Director, Office of Community Services.

[FR Doc. 03–29837 Filed 11–28–03; 8:45 am]

BILLING CODE 4184–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2003N–0200]

Agency Information Collection Activities; Announcement of OMB Approval; Export of Medical Devices—Foreign Letters of Approval

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled ''Export of Medical Devices—Foreign Letters of Approval'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Peggy Robbins, Office of Management Programs (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1223.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of August 25, 2003 (68 FR 51023), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0264. The approval expires on November 30, 2006. A copy of the supporting statement for this information collection is available on the Internet at *http://www.fda.gov/ohrms/dockets*.

Dated: November 21, 2003.

Jeffrey Shuren,

Assistant Commissioner for Policy.

[FR Doc. 03–29743 Filed 11–28–03; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2003N–0194]

Agency Information Collection Activities; Announcement of OMB Approval; Agreement for Shipment of Devices for Sterilization

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled ''Agreement for Shipment of Devices for Sterilization'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Peggy Robbins, Office of Management Programs (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1223.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of August 12, 2003 (68 FR 47919), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0131. The approval expires on November 30, 2006. A copy of the supporting statement for this information collection is available on the Internet at *http://www.fda.gov/ohrms/dockets*.

Dated: November 21, 2003.

Jeffrey Shuren,

Assistant Commissioner for Policy.

[FR Doc. 03–29745 Filed 11–28–03; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2003E–0246]

Determination of Regulatory Review Period for Purposes of Patent Extension; DERAMAXX

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for DERAMAXX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.

ADDRESSES: Submit written comments and petitions to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to *http://www.fda.gov/dockets/ecomments*.

FOR FURTHER INFORMATION CONTACT: Claudia Grillo, Office of Regulatory Policy (HFD–013), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 240–453–6699.

SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98–417) and the Generic Animal Drug and Patent Term Restoration Act (Public Law 100–670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug